The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
Feature|Articles|May 21, 2026
Frontline Combos Take the Spotlight: Previewing the Top Hematologic Oncology Presentations at ASCO 2026
Author(s)Chris Ryan, Riley Kandel
Hematologic oncology experts preview the top ASCO 2026 abstracts to watch in myeloma, MPNs, large B-cell lymphoma, and more.
Advertisement
Advertisement
With the
Related to this article
The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The phase 3 INTREPID trial is evaluating sapablursen in phlebotomy-dependent polycythemia vera.
Subcutaneous amivantamab produced a 42% objective response rate and a 15% complete response rate in patients with recurrent/metastatic HNSCC.
Patients who received MBTF prior to allo-HSCT achieved promising survival outcomes and manageable safety in relapsed/refractory acute myeloid leukemia.
Sagar Lonial, MD, FACP, FASCO, and Sikander Ailawadhi, MD, discuss the investigation of cemsidomide in relapsed/refractory multiple myeloma.
Teclistamab-based induction generated a 91.8% MRD-negative complete response rate with a manageable safety profile in multiple myeloma.
Advertisement
Advertisement